Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773586 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL18043490 | 0.83 | EPHX2 (0.56) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL18043489 | 0.83 | EPHX2 (0.56) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL15091510 | 0.82 | KDM1A (0.71) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL12971952 | 0.82 | KDM1A (0.71) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL239614 | 0.82 | KDM1A (0.67) | KDM1AMAOAMAOB | |
| SCHEMBL11903677 | 0.82 | NPC1 (0.48) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL239613 | 0.82 | KDM1A (0.67) | KDM1AMAOAMAOB | |
| SCHEMBL11903680 | 0.82 | NPC1 (0.48) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL14882063 | 0.81 | MME (0.46) | SMN1; SMN2NPSR1KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | SMN1; SMN2 3062/4885NPSR1 3482/4885KDM1A 1482/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | SMN1; SMN2 47/4885NPSR1 1421/4885KDM1A 3423/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | SMN1; SMN2 47/4885NPSR1 1421/4885KDM1A 3423/4885 |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | SMN1; SMN2 2788/4885NPSR1 2678/4885KDM1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.